Search | Clinical Trials Finder

Conditions: Obstructive Sleep Apnea Syndrome
Interventions: tonsillectomy; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Months to 12 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fever
Interventions: text message surveillance for fever; Other
Lead sponsor: Columbia University; Other
Eligibility: 24 Months to 59 Months
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Motor Vehicle Accident, Interaction, Parent-Offspring
Interventions: Hazard Anticipation Program for Parents of Teen Drivers; Behavioral
Lead sponsor: Elizabeth O'Neal; Other
Eligibility: 14 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions: Tegavivint, Gemcitabine; Drug
Lead sponsor: Emory University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions: somatropin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 18 Years
Enrollment: 22,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Autism Spectrum Disorder, Mental Health Services
Interventions: Access to a Family Service Navigator and Treatment Support System; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Interventions: Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Year to 31 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 3 more

Conditions: Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, filgrastim, laboratory biomarker analysis, pharmacological study; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Anxiety, Laceration Repair, Children
Interventions: iPad, Standard Care; Device · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 2 Years to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Morbid Obesity
Interventions: Bariatric surgery.; Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Brain Tumors
Interventions: Ketogenic Diet; Other
Lead sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital; Other
Eligibility: 12 Months to 35 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Children
Interventions: Gadoquatrane (BAY1747846); Drug
Lead sponsor: Bayer; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Indian Wells, California • Kansas City, Missouri • Charleston, South Carolina

Conditions: Exercise, Women, Hispanic Americans, Child
Interventions: Intervention; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 8 Years to 65 Years · Female only
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions: AZLI, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more

Conditions: Pediatric Intensive Care Unit
Interventions: Not listed
Lead sponsor: Akron Children's Hospital; Other
Eligibility: Up to 15 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Athletic Injuries
Interventions: Diclofenac hydroxyethylpyrrolidine; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Little Rock, Arkansas • St. Petersburg, Florida • Marietta, Georgia + 5 more

Conditions: Child Behavior Problems
Interventions: Immediate CARE; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Human Immunodeficiency Virus (HIV) Infection
Interventions: Doravirine, 2 NRTIs, DOR/3TC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 4 Weeks to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 2
States / cities: Aurora, Colorado • Atlanta, Georgia

Conditions: Vomiting, Nausea, Children, Only
Interventions: Inhaled Isopropyl Alcohol, Oral Ondansetron, Inhaled Placebo; Other · Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 7 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more

Conditions: One-lung Ventilation (OLV)
Interventions: Intracuff pressure measurement in one-lung ventilation during thoracic surgery; Procedure
Lead sponsor: Joseph D. Tobias; Other
Eligibility: Up to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Developmental Delay, Mental Health Disorder
Interventions: H3 Services; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Up to 16 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 1
Interventions: Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Physical Activities
Interventions: We Move with Windy; Behavioral
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 3 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

Cytokine Profiles in Children With Obstructive Sleep Apnea

Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014

Hazard Anticipation Program for Parents of Teen Drivers

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

Testing a Family Service Navigator Program for Low-resourced Families of Young Children With Autism Spectrum Disorder

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

iPad as a Distraction Tool During Facial Laceration Repair

Bariatric Surgery Outcomes

Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

Conmigo: A Mother-daughter Intervention to Promote Physical Activity

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

A Critical Appraisal of the Role of Near Infrared Spectroscopy (NIRS) in the Pediatric Intensive Care Unit (PICU)

Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

Parent Program to Improve Child Behavior Problems

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Inhaled Isopropyl Alcohol for Treatment of Nausea

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Intracuff Pressure During One-lung Ventilation in Infants and Children

H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation

Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

We-Move With Windy: Gross Motor Development for Early Childhood